Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 0.70 |
| ▸ | ICAM1 | P05362 | 20/20 | 0.70 |
| ▸ | ITGAL | P20701 | 20/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22296813 | 0.99 | ITGB2 (0.69) | ITGB2ICAM1ITGAL | |
| SCHEMBL13813582 | 0.99 | ITGB2 (0.69) | ITGB2ICAM1ITGAL | |
| SCHEMBL23992593 | 0.93 | ITGB2 (0.64) | ITGB2ICAM1ITGAL | |
| SCHEMBL4756084 | 0.92 | ITGB2 (0.67) | ITGB2ICAM1ITGAL | |
| SCHEMBL25912527 | 0.92 | ITGB2 (0.73) | ITGB2ICAM1ITGAL | |
| SCHEMBL4755948 | 0.92 | ITGB2 (0.66) | ITGB2ICAM1ITGAL | |
| SCHEMBL12169832 | 0.92 | ITGB2 (0.66) | ITGB2ICAM1ITGAL | |
| SCHEMBL17992523 | 0.92 | ITGB2 (0.66) | ITGB2ICAM1ITGAL | |
| SCHEMBL18868110 | 0.91 | ITGB2 (0.66) | ITGB2ICAM1ITGAL | |
| SCHEMBL12169799 | 0.91 | ITGB2 (0.66) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233551-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-07-27 | — | — | US | disclosed |
| US-10188641-B2 | Compositions and methods for treatment | SARCODE BIOSCIENCE INC. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3195861-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DRY EYE DISORDERS | SARcode Bioscience Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20170143693-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143692-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143692-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143691-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143690-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143691-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143690-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-8168655-B2 | Compositions and methods for treatment of eye disorders | SARCODE BIOSCIENCE INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168655-B2 | Compositions and methods for treatment of eye disorders | SARCODE BIOSCIENCE INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8084047-B2 | Compositions and methods for treatment of eye disorders | SARCODE BIOSCIENCE INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084047-B2 | Compositions and methods for treatment of eye disorders | SARCODE BIOSCIENCE INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110165228-A1 | Compositions and Methods for Treatment | SARCODE CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165228-A1 | Compositions and Methods for Treatment | SARCODE CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100092541-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-04-15 | — | — | US | disclosed |
| US-20100092542-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2010-04-15 | — | — | US | disclosed |
| US-20100092541-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-04-15 | — | — | US | disclosed |
| US-20100092542-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165228-A1 | Compositions and Methods for Treatment | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20170143692-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20170143693-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20170143691-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20230233551-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20170143690-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20100092541-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-10188641-B2 | Compositions and methods for treatment | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20100092542-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.